title: [Circulating immune complexes in patients with lymphoproliferative and myeloproliferative diseases].
abstract: Circulating immune complexes have been studied with a competitive immune-enzymatic method on 9 controls, on 34 patients with lymphoproliferative disease (41.6 +/- 26.8) and in those with myeloproliferative disease (62.1 +/- 30) have been found significantly higher than in controls (20.3 +/- 14.1). The percentage of incidence of circulating immune complexes with values greater than 35 (normal value greater than 35) is found to be 58.8% in lymphoproliferative disease and 77.7% in myeloproliferative disease. Higher values of circulating immune complexes have been observed in patients with a depressed count of circulating monocytes, of lymphocytes with a dot-like alpha-naphthyl-acetate-esterase reaction and of nitroblue tetrazolium positive granulocytes, suggesting that circulating immune complexes can modulate cellular immune response as blocking factors.
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000936:Antigen-Antibody Complex / Q000032:analysis*; D002648:Child; D002675:Child, Preschool; D003937:Diagnosis, Differential; D005260:Female; D006689:Hodgkin Disease / Q000276:immunology; D006801:Humans; D006942:Hypergammaglobulinemia / Q000276:immunology; D007223:Infant; D007945:Leukemia, Lymphoid / Q000276:immunology; D007951:Leukemia, Myeloid / Q000276:immunology; D015470:Leukemia, Myeloid, Acute / Q000276:immunology; D008223:Lymphoma / Q000276:immunology; D008232:Lymphoproliferative Disorders / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000276:immunology; D009196:Myeloproliferative Disorders / Q000276:immunology*; D011087:Polycythemia Vera / Q000276:immunology; D055728:Primary Myelofibrosis / Q000276:immunology; D011379:Prognosis; D008258:Waldenstrom Macroglobulinemia / Q000276:immunology
chemical_list: D000936:Antigen-Antibody Complex
vernacular_title: Immunocomplessi circolanti in pazienti con malattie linfoproliferative e mieloproliferative.